Endocrine Abstracts

Introduction: Denosumab is a new pharmacotherapy option for postmenopausal osteoporosis. It is a human monoclonal antibody against RANKL, acting as an osteoprotegerin (OPG) analog. Recently, osteoprotegerin levels were found to be elevated in type two diabetes while insulin resistance was shown to be positively associated with decreased serum OPG levels, in healthy obese subjects. However, no study has been conducted in order to clarify the effect of anti-RANKL factors adminis...

Introduction: Partial androgen insensitivity syndrome (PAIS) is a heterogeneous group of intersex disorders arising from tissue resistance to androgen action due to mutations of the androgen receptor. The phenotypic expression of the syndrome varies considerably and external genitalia’s masculinization depends on residual activity of the androgen receptor while gynecomastia is observed in most of the cases.Case report: We present the case of a 16 ye...